Cellectis S.A. (NASDAQ:CLLS) went up by 15.21% from its latest closing price compared to the recent 1-year high of $9.57. The company’s stock price has collected 14.16% of gains in the last five trading sessions.
Is It Worth Investing in Cellectis S.A. (NASDAQ :CLLS) Right Now?
Plus, the 36-month beta value for CLLS is at 2.03. Opinions of the stock are interesting as 5 analysts out of 11 who provided ratings for Cellectis S.A. declared the stock was a “buy,” while 2 rated the stock as “overweight,” 3 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $11.80, which is $9.3 above the current price. CLLS currently public float of 45.37M and currently shorts hold a 1.28% ratio of that float. Today, the average trading volume of CLLS was 81.13K shares.
CLLS’s Market Performance
CLLS stocks went up by 14.16% for the week, with a monthly jump of 5.49% and a quarterly performance of -25.60%, while its annual performance rate touched -70.02%. The volatility ratio for the week stands at 5.41% while the volatility levels for the past 30 days are set at 6.51% for Cellectis S.A. The simple moving average for the period of the last 20 days is 6.92% for CLLS stocks with a simple moving average of -25.10% for the last 200 days.
Analysts’ Opinion of CLLS
Many brokerage firms have already submitted their reports for CLLS stocks, with Robert W. Baird repeating the rating for CLLS by listing it as a “Outperform.” The predicted price for CLLS in the upcoming period, according to Robert W. Baird is $10 based on the research report published on May 18th of the current year 2022.
Wells Fargo, on the other hand, stated in their research note that they expect to see CLLS reach a price target of $16, previously predicting the price at $39. The rating they have provided for CLLS stocks is “Equal Weight” according to the report published on January 06th, 2022.
JMP Securities gave a rating of “Mkt Outperform” to CLLS, setting the target price at $20 in the report published on November 30th of the previous year.
CLLS Trading at 1.95% from the 50-Day Moving Average
After a stumble in the market that brought CLLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.88% of loss for the given period.
Volatility was left at 6.51%, however, over the last 30 days, the volatility rate increased by 5.41%, as shares sank -3.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.24% lower at present.
During the last 5 trading sessions, CLLS rose by +14.16%, which changed the moving average for the period of 200-days by -55.28% in comparison to the 20-day moving average, which settled at $2.33. In addition, Cellectis S.A. saw -69.21% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CLLS
Current profitability levels for the company are sitting at:
- -245.15 for the present operating margin
- +45.26 for the gross margin
The net margin for Cellectis S.A. stands at -199.32. The total capital return value is set at -37.35, while invested capital returns managed to touch -33.26. Equity return is now at value -62.00, with -33.50 for asset returns.
Based on Cellectis S.A. (CLLS), the company’s capital structure generated 45.58 points at debt to equity in total, while total debt to capital is 31.31. Total debt to assets is 26.40, with long-term debt to equity ratio resting at 40.80. Finally, the long-term debt to capital ratio is 28.03.
When we switch over and look at the enterprise to sales, we see a ratio of 1.49, with the company’s debt to enterprise value settled at 0.33. The receivables turnover for the company is 2.25 and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.57.